- Home
- EVGN vs NLSP Comparison
EVGN vs NLSP Comparison
Compare EVGN & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGN
- NLSP
- Stock Information
- Founded
- EVGN 1999
- NLSP 2015
- Country
- EVGN Israel
- NLSP Switzerland
- Employees
- EVGN N/A
- NLSP N/A
- Industry
- EVGN Agricultural Chemicals
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- EVGN Industrials
- NLSP Health Care
- Exchange
- EVGN Nasdaq
- NLSP Nasdaq
- Market Cap
- EVGN 11.6M
- NLSP 12.4M
- IPO Year
- EVGN N/A
- NLSP 2021
- Fundamental
- Price
- EVGN $1.24
- NLSP $2.03
- Analyst Decision
- EVGN Strong Buy
- NLSP
- Analyst Count
- EVGN 1
- NLSP 0
- Target Price
- EVGN $3.50
- NLSP N/A
- AVG Volume (30 Days)
- EVGN 55.7K
- NLSP 173.4K
- Earning Date
- EVGN 08-19-2025
- NLSP 10-17-2025
- Dividend Yield
- EVGN N/A
- NLSP N/A
- EPS Growth
- EVGN N/A
- NLSP N/A
- EPS
- EVGN N/A
- NLSP N/A
- Revenue
- EVGN $9,444,000.00
- NLSP N/A
- Revenue This Year
- EVGN N/A
- NLSP N/A
- Revenue Next Year
- EVGN $63.64
- NLSP N/A
- P/E Ratio
- EVGN N/A
- NLSP N/A
- Revenue Growth
- EVGN N/A
- NLSP N/A
- 52 Week Low
- EVGN $0.95
- NLSP $1.30
- 52 Week High
- EVGN $3.35
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- EVGN 46.32
- NLSP 41.38
- Support Level
- EVGN $1.26
- NLSP $2.03
- Resistance Level
- EVGN $1.33
- NLSP $2.29
- Average True Range (ATR)
- EVGN 0.07
- NLSP 0.19
- MACD
- EVGN -0.00
- NLSP -0.06
- Stochastic Oscillator
- EVGN 20.48
- NLSP 1.28
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.